Renal Denervation: Patient Selection and When to Refer

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology

Background:

• Hypertension remains a leading global health concern.
• Resistant hypertension poses significant challenges in patient management.
• The US Food and Drug Administration (FDA) approved renal denervation in November 2023.

Purpose of the Study:

• To review current data on patient selection for renal denervation.
• To provide guidance on referring patients with uncontrolled hypertension for this therapy.

Main Methods:

• Systematic review of clinical trial data.
• Analysis of patient outcomes following renal denervation procedures.
• Evaluation of different denervation methodologies.

Main Results:

• Most patients achieved clinically significant blood pressure reduction post-procedure.
• Variability in response observed across different patient cohorts and methodologies.
• Identification of key factors influencing treatment success.

Conclusions:

• Renal denervation is a promising therapeutic option for select patients with uncontrolled hypertension.
• Careful patient selection is crucial for optimizing outcomes.
• Further research is needed to refine patient selection criteria and long-term efficacy.